Billionaire Puig Empire to Weigh Share Buyback in Time, CEO Says
Shares of Puig, owner of perfume brands like Jean Paul Gaultier and makeup label Charlotte Tilbury, have tumbled more than 34% since its splashy listing just over a year ago as Europe's biggest IPO in 2024.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
3 Asian Penny Stocks With Market Caps Below US$10B
Amid a backdrop of favorable trade deals and positive market sentiment, Asian markets have been buoyed by renewed optimism. This environment provides a fertile ground for penny stocks, which, despite the outdated terminology, continue to offer intriguing opportunities for investors. These stocks typically represent smaller or newer companies that can combine affordability with growth potential when supported by strong financials and fundamentals. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Food Moments (SET:FM) THB4.02 THB3.97B ★★★★★☆ Lever Style (SEHK:1346) HK$1.46 HK$921.19M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.51 HK$2.09B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.485 SGD196.57M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.20 HK$2B ★★★★★★ T.A.C. Consumer (SET:TACC) THB4.60 THB2.76B ★★★★★★ China Sunsine Chemical Holdings (SGX:QES) SGD0.70 SGD667.37M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.54 SGD10B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.95 THB1.4B ★★★★★★ Livestock Improvement (NZSE:LIC) NZ$0.95 NZ$135.23M ★★★★★★ Click here to see the full list of 970 stocks from our Asian Penny Stocks screener. Let's take a closer look at a couple of our picks from the screened companies. Alibaba Health Information Technology Simply Wall St Financial Health Rating: ★★★★★★ Overview: Alibaba Health Information Technology Limited is an investment holding company that operates in pharmaceutical direct sales, pharmaceutical e-commerce platforms, and healthcare and digital services in Mainland China and Hong Kong, with a market cap of approximately HK$77.99 billion. Operations: The company's revenue from the distribution and development of pharmaceutical and healthcare products is CN¥30.60 billion. Market Cap: HK$77.99B Alibaba Health Information Technology has demonstrated significant earnings growth, with a notable increase of 62.1% over the past year, surpassing its five-year average of 52.2%. The company reported revenues of CN¥30.60 billion for the fiscal year ending March 31, 2025, and improved net profit margins to 4.7%. Despite a one-off loss impacting recent results, Alibaba Health remains debt-free and trades below its estimated fair value by approximately 12.6%. Its short-term assets comfortably cover both short- and long-term liabilities, although the board's average tenure is relatively inexperienced at three years. Click here and access our complete financial health analysis report to understand the dynamics of Alibaba Health Information Technology. Gain insights into Alibaba Health Information Technology's future direction by reviewing our growth report. Shanghai Trendzone Holdings GroupLtd Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Shanghai Trendzone Holdings Group Co., Ltd, with a market cap of CN¥3.74 billion, offers integrated solutions in design, construction, production, and services both in China and internationally. Operations: No specific revenue segments have been reported for Shanghai Trendzone Holdings Group Co., Ltd. Market Cap: CN¥3.74B Shanghai Trendzone Holdings Group Co., Ltd, with a market cap of CN¥3.74 billion, has shown some financial resilience despite being unprofitable. Its short-term assets of CN¥1.3 billion comfortably cover both short- and long-term liabilities, indicating solid liquidity management. The company's debt to equity ratio has improved over five years to 42.5%, suggesting prudent debt management, while its net debt to equity ratio is satisfactory at 35.3%. However, the firm remains unprofitable with a negative return on equity of -9.78% and faces high share price volatility alongside less than one year of cash runway based on current free cash flow trends. Dive into the specifics of Shanghai Trendzone Holdings GroupLtd here with our thorough balance sheet health report. Assess Shanghai Trendzone Holdings GroupLtd's previous results with our detailed historical performance reports. Leo Group Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Leo Group Co., Ltd. operates in China through its subsidiaries, focusing on the research, development, manufacture, and sale of pumps and garden machinery products with a market cap of CN¥24.94 billion. Operations: No specific revenue segments are reported for Leo Group Co., Ltd. Market Cap: CN¥24.94B Leo Group Co., Ltd. has a market cap of CN¥24.94 billion and operates in China, focusing on pumps and garden machinery products. Despite having more cash than total debt, its operating cash flow covers only 12.3% of the debt, indicating potential liquidity concerns. The company's net profit margin decreased to 0.4% from 5.6% last year, with earnings declining by 33.2% annually over five years due to a significant one-off loss of CN¥388.7M affecting recent results as of March 2025. While short-term assets exceed liabilities significantly, the dividend yield remains poorly covered by earnings or free cash flows. Unlock comprehensive insights into our analysis of Leo Group stock in this financial health report. Evaluate Leo Group's historical performance by accessing our past performance report. Key Takeaways Embark on your investment journey to our 970 Asian Penny Stocks selection here. Looking For Alternative Opportunities? The latest GPUs need a type of rare earth metal called Neodymium and there are only 25 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:241 SHSE:603030 and SZSE:002131. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
If EPS Growth Is Important To You, Ricegrowers (ASX:SGLLV) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should. Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Ricegrowers (ASX:SGLLV). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Ricegrowers with the means to add long-term value to shareholders. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Ricegrowers' Earnings Per Share Are Growing Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. That makes EPS growth an attractive quality for any company. Over the last three years, Ricegrowers has grown EPS by 9.8% per year. That's a pretty good rate, if the company can sustain it. Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. It seems Ricegrowers is pretty stable, since revenue and EBIT margins are pretty flat year on year. While this doesn't ring alarm bells, it may not meet the expectations of growth-minded investors. You can take a look at the company's revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers. View our latest analysis for Ricegrowers While we live in the present moment, there's little doubt that the future matters most in the investment decision process. So why not check this interactive chart depicting future EPS estimates, for Ricegrowers? Are Ricegrowers Insiders Aligned With All Shareholders? It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. Shareholders will be pleased by the fact that insiders own Ricegrowers shares worth a considerable sum. To be specific, they have AU$29m worth of shares. That shows significant buy-in, and may indicate conviction in the business strategy. Even though that's only about 3.9% of the company, it's enough money to indicate alignment between the leaders of the business and ordinary shareholders. Should You Add Ricegrowers To Your Watchlist? As previously touched on, Ricegrowers is a growing business, which is encouraging. To add an extra spark to the fire, significant insider ownership in the company is another highlight. That combination is very appealing. So yes, we do think the stock is worth keeping an eye on. You still need to take note of risks, for example - Ricegrowers has 1 warning sign we think you should be aware of. Although Ricegrowers certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of Australian companies that not only boast of strong growth but have strong insider backing. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
CNN
27 minutes ago
- CNN
In a deal with Trump, Europe gets an elusive agreement. But everyone's a little annoyed
Tariffs European Union Prescription drugsFacebookTweetLink Follow The United States and the European Union avoided the worst-case scenario: a damaging, all-out trade war between allies that threatened to raise prices on a large number of goods and slow two of the world's largest economies. The framework delivered a sense of relief for both sides – but few are cheering the arrangement itself. The agreement, which sets a 15% tariff on most European goods entering the United States, is higher than the 10% tariff Trump put in place on April 2 and significantly higher than the average of around 2% from before Trump's presidency. But it's significantly less than the enormous numbers Trump had been threatening if an agreement wasn't reached. A deal with the United States felt like an impossibility in late May. Frustrated by a lack of progress in negotiations with the 27-member European Union, Trump on May 24 told the world he was done talking to some of America's strongest allies. 'Our discussions with them are going nowhere!' Trump posted on Truth Social. 'I'm not looking for a deal,' he said later that day in the Oval Office. 'We've set the deal — it's at 50%.' The statement — and the shockingly high tariff threat — stunned European trade negotiators and rallied Europe's leaders into action. They quickly agreed to kick talks into high gear. Trump, who has taken a particular liking to European Commission President Ursula von der Leyen, was swayed after she called him to say the EU would commit to moving 'swiftly and decisively.' Trump soon backed off his threat and said negotiations would continue. But a deal between the United States and the European Union, one of America's top trading partners, had remained elusive for months. The two sides squabbled over America's insistence on high tariffs for steel and aluminum, looming tariffs on pharmaceuticals and the tariff floor for virtually all goods that the Trump administration appears set to raise to 15%. Negotiators were unable to come up with a resolution before the initial July 9 deadline — one of the reasons the Trump administration postponed the effective day for its 'reciprocal' tariffs to August 1. With just days to go before the extended deadline, while Trump was visiting Scotland, he met with van der Leyen and finalized a framework for an agreement — one that was thin on details, heavy on caveats, but was nevertheless a hard-sought relief for both sides. With the agreement in place, two of the world's largest economies avoided a potential economically crippling trade war. The United States held a 50% tariff threat over Europe's head, and Europe threatened America with strategic retaliatory tariffs that threatened to damage key US industries. Both sides appeared to embrace the fact that a deal was in place more than they celebrated it. 'We made it,' Trump said while announcing the deal with von der Leyen. 'It's going to work out really well.' 'I think we hit exactly the point we wanted to find,' von der Leyen said. 'Rebalance but enable trade on both sides. Which means good jobs on both sides of the Atlantic, means prosperity on both sides of the Atlantic and that was important for us.' Markets cheered, somewhat: Dow futures rose 150 points, or 0.3%, poised to open near record territory. S&P 500 futures gained 0.3% and Nasdaq futures were 0.4% higher. The United States and Europe 'seem to have avoided a self-destructive trade war for now in the biggest and deepest commercial and investment relationship the global economy knows,' said Jörn Fleck, senior director of the Atlantic Council's Europe Center. Nevertheless, the details remain murky. Europe will increase its investment in the United States by $600 billion and commit to buying $750 billion worth of US energy products. It eliminates tariffs on a variety of items, including aircraft and plane parts, semiconductors, generic drugs and some chemicals and agricultural products. Industries in the zero-tariff arrangement cheered. 'The zero-for-zero tariff regime will grow jobs, strengthen our economic security and provide a framework for U.S. leadership in manufacturing and safety,' Airlines for America said in a statement. But the 15% baseline tariff applies to most goods, so the EU member states – and American importers — will have to come to terms with the fact that higher tariffs will raise prices for European goods in America. 'Higher tariffs mean higher prices for US consumers—and that will seriously dent EU companies' bottom lines,' said Alex Altmann, vice president of the British Chamber of Commerce in Germany. 'EU companies aiming to stay competitive in the US market will think twice when deciding where to produce or assemble.' The agreement also deals another blow to Detroit automakers, which objected to a similar deal the Trump administration reached with Japan. The 15% auto tariff on EU cars imported to the United States undercuts the 25% tariff American automakers pay if their cars are built in Mexico. Although von der Leyen said pharmaceuticals were included in the early framework, she acknowledged that Trump may ultimately place higher tariffs on drugs imported to the United States, undercutting the agreement. Still, in the eyes of the hard-working negotiators — and for the sake of the global economy — a deal is better than no deal. Now comes the hard part: figuring out the details.
